

REMARKS

Claim 40 has been amended to correct a typographical error. Claims 1-27 and 38 were previously canceled. Claims 28-37 and 39-40 are currently pending in this application.

The Examiner has required restriction between Group I, claim 39 drawn to a method of inhibiting the expression of PC Cell Derived Growth Factor protein in a cell comprising administering a PC Cell Derived Growth Factor antisense oligonucleotide comprising SEQ ID NO: 14 to the cell and Group II, claim 40, drawn to a method of inhibiting the expression of PC Cell Derived Growth Factor protein in a cell comprising administering a PC Cell Derived Growth Factor antisense oligonucleotide comprising SEQ ID NO: 12. Applicant has elected Group I, claim 39, for continued prosecution without traverse.

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to pass this application to issue. If the Examiner should believe that anything further may be required to place this application in even better form for allowance, she is cordially invited to telephone the undersigned attorneys for Applicant.

Dated: May 11, 2007

Respectfully submitted,

By 

Jeremy A. Cubert

Registration No.: 40,399

Elizabeth Parsons

Registration No.: 52,499

DICKSTEIN SHAPIRO LLP

1825 Eye Street, NW

Washington, DC 20006-5403

(202) 420-2200

Attorneys for Applicant